Two successful exits – Syndesi and BioPhero Four portfolio companies reported clinical data from first in class targets (Galecto, NMD Pharma, Heparegenix and MinervaX) Led three new seed investments and incubating additional projects Expanded team as part of strong investment in global talent to access innovation REPAIR Impact Fund making strides in the vital combat […]